Skip to main content
Erschienen in: Archives of Dermatological Research 3/2018

24.01.2018 | Original Paper

Phenotyping acute and chronic atopic dermatitis-like lesions in Stat6VT mice identifies a role for IL-33 in disease pathogenesis

verfasst von: Sonia C. DaSilva-Arnold, Anita Thyagarajan, Leroy J. Seymour, Qiaofang Yi, Joshua R. Bradish, Mohammed Al-Hassani, Hongming Zhou, Nikolajs J. Perdue, Val Nemeth, Aleksandar Krbanjevic, Ana P. M. Serezani, Matthew R. Olson, Dan F. Spandau, Jeffrey B. Travers, Mark H. Kaplan, Matthew J. Turner

Erschienen in: Archives of Dermatological Research | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

The Stat6VT mouse model of atopic dermatitis (AD) is induced by T-cell-specific expression of a constitutively active form of the protein signal transducer and activator of transcription 6 (STAT6). Although AD-like lesions are known to develop in Stat6VT mice, this study was designed to determine if these mice develop acute and chronic phases of disease similar to humans. To address this, AD-like lesions from Stat6VT mice were harvested at two different timepoints relative to their onset. Lesions harvested within 1 week after development were defined as acute lesions, and those present for 1 month or more were defined as chronic lesions. Acute and chronic AD-like lesions from Stat6VT mice exhibited histologic findings and cytokine expression patterns similar to acute and chronic AD lesions in humans. Further analysis revealed increased levels of interleukin (IL)-33 transcripts in AD-like lesions compared to Stat6VT nonlesional and wild-type skin controls. Immunofluorescence also revealed increased numbers of IL-33+ keratinocytes in Stat6VT lesional skin and localized IL-33+ keratinocytes to a keratin 5+ subset. Furthermore, AD-like disease was more severe in IL-33-deficient Stat6VT mice compared to IL-33-sufficient Stat6VT mice. These studies suggest that Stat6VT mice can serve as a model of acute and chronic AD and that IL-33 may attenuate inflammation in this system.
Literatur
1.
Zurück zum Zitat Ali S et al (2007) IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci USA 104:18660–18665CrossRefPubMedPubMedCentral Ali S et al (2007) IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci USA 104:18660–18665CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Ali S et al (2011) The dual function cytokine IL-33 interacts with the transcription factor NF-kappaB to dampen NF-kappaB-stimulated gene transcription. J Immunol 187:1609–1616CrossRefPubMed Ali S et al (2011) The dual function cytokine IL-33 interacts with the transcription factor NF-kappaB to dampen NF-kappaB-stimulated gene transcription. J Immunol 187:1609–1616CrossRefPubMed
4.
Zurück zum Zitat Beck LA et al (2014) Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371:130–139CrossRefPubMed Beck LA et al (2014) Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371:130–139CrossRefPubMed
6.
Zurück zum Zitat Brunner SM et al (2011) Interleukin-33 prolongs allograft survival during chronic cardiac rejection. Transpl Int 24:1027–1039CrossRefPubMed Brunner SM et al (2011) Interleukin-33 prolongs allograft survival during chronic cardiac rejection. Transpl Int 24:1027–1039CrossRefPubMed
7.
Zurück zum Zitat Bruns HA et al (2003) Expression of a constitutively active Stat6 in vivo alters lymphocyte homeostasis with distinct effects in T and B cells. J Immunol 170:3478–3487CrossRefPubMed Bruns HA et al (2003) Expression of a constitutively active Stat6 in vivo alters lymphocyte homeostasis with distinct effects in T and B cells. J Immunol 170:3478–3487CrossRefPubMed
8.
Zurück zum Zitat Carriere V et al (2007) IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA 104:282–287CrossRefPubMed Carriere V et al (2007) IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA 104:282–287CrossRefPubMed
9.
Zurück zum Zitat Chackerian AA et al (2007) IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 179:2551–2555CrossRefPubMed Chackerian AA et al (2007) IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 179:2551–2555CrossRefPubMed
10.
Zurück zum Zitat Choi YS et al (2012) Nuclear IL-33 is a transcriptional regulator of NF-kappaB p65 and induces endothelial cell activation. Biochem Biophys Res Commun 421:305–311CrossRefPubMed Choi YS et al (2012) Nuclear IL-33 is a transcriptional regulator of NF-kappaB p65 and induces endothelial cell activation. Biochem Biophys Res Commun 421:305–311CrossRefPubMed
11.
12.
Zurück zum Zitat DaSilva SC et al (2012) Increased skin barrier disruption by sodium lauryl sulfate in mice expressing a constitutively active STAT6 in T cells. Arch Dermatol Res 304:65–71CrossRefPubMed DaSilva SC et al (2012) Increased skin barrier disruption by sodium lauryl sulfate in mice expressing a constitutively active STAT6 in T cells. Arch Dermatol Res 304:65–71CrossRefPubMed
13.
Zurück zum Zitat Dillon SR et al (2004) Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 5:752–760CrossRefPubMed Dillon SR et al (2004) Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 5:752–760CrossRefPubMed
14.
Zurück zum Zitat Duan L et al (2012) Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3(+) regulatory T-cell responses in mice. Mol Med 18:753–761CrossRefPubMedPubMedCentral Duan L et al (2012) Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3(+) regulatory T-cell responses in mice. Mol Med 18:753–761CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Ewald DA et al (2017) Major differences between human atopic dermatitis and murine models, as determined by using global transcriptomic profiling. J Allergy Clin Immunol 139:562–571CrossRefPubMed Ewald DA et al (2017) Major differences between human atopic dermatitis and murine models, as determined by using global transcriptomic profiling. J Allergy Clin Immunol 139:562–571CrossRefPubMed
16.
Zurück zum Zitat Gajardo T et al (2015) Exogenous interleukin-33 targets myeloid-derived suppressor cells and generates periphery-induced Foxp3(+) regulatory T cells in skin-transplanted mice. Immunology 146:81–88CrossRefPubMedPubMedCentral Gajardo T et al (2015) Exogenous interleukin-33 targets myeloid-derived suppressor cells and generates periphery-induced Foxp3(+) regulatory T cells in skin-transplanted mice. Immunology 146:81–88CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Gandhi NA et al (2016) Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 15:35–50CrossRefPubMed Gandhi NA et al (2016) Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 15:35–50CrossRefPubMed
19.
Zurück zum Zitat Hanifin JM et al (2001) The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 10:11–18CrossRef Hanifin JM et al (2001) The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 10:11–18CrossRef
20.
Zurück zum Zitat Imai Y et al (2013) Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc Natl Acad Sci USA 110:13921–13926CrossRefPubMedPubMedCentral Imai Y et al (2013) Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc Natl Acad Sci USA 110:13921–13926CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Jiang HR et al (2012) IL-33 attenuates EAE by suppressing IL-17 and IFN-gamma production and inducing alternatively activated macrophages. Eur J Immunol 42:1804–1814CrossRefPubMed Jiang HR et al (2012) IL-33 attenuates EAE by suppressing IL-17 and IFN-gamma production and inducing alternatively activated macrophages. Eur J Immunol 42:1804–1814CrossRefPubMed
23.
Zurück zum Zitat Kim BS et al (2013) TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Sci Transl Med 5:170ra116CrossRef Kim BS et al (2013) TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Sci Transl Med 5:170ra116CrossRef
24.
Zurück zum Zitat Kouzaki H et al (2011) The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J Immunol 186:4375–4387CrossRefPubMedPubMedCentral Kouzaki H et al (2011) The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J Immunol 186:4375–4387CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Li M et al (2006) Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis. Proc Natl Acad Sci USA 103:11736–11741CrossRefPubMedPubMedCentral Li M et al (2006) Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis. Proc Natl Acad Sci USA 103:11736–11741CrossRefPubMedPubMedCentral
26.
27.
Zurück zum Zitat Matsuda H et al (1997) Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol 9:461–466CrossRefPubMed Matsuda H et al (1997) Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol 9:461–466CrossRefPubMed
28.
Zurück zum Zitat Matta BM et al (2014) IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2 + regulatory T cells. J Immunol 193:4010–4020CrossRefPubMedPubMedCentral Matta BM et al (2014) IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2 + regulatory T cells. J Immunol 193:4010–4020CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Matta BM et al (2016) Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD. Blood 128:427–439CrossRefPubMedPubMedCentral Matta BM et al (2016) Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD. Blood 128:427–439CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Monticelli LA et al (2015) IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions. Proc Natl Acad Sci USA 112:10762–10767CrossRefPubMedPubMedCentral Monticelli LA et al (2015) IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions. Proc Natl Acad Sci USA 112:10762–10767CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Moussion C et al. (2008) The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’?. PloS One. 3, e3331 Moussion C et al. (2008) The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’?. PloS One. 3, e3331
32.
Zurück zum Zitat Noel G et al (2016) Ablation of interaction between IL-33 and ST2 + regulatory T cells increases immune cell-mediated hepatitis and activated NK cell liver infiltration. Am J Physiol Gastrointest Liver Physiol 311:G313–G323CrossRefPubMed Noel G et al (2016) Ablation of interaction between IL-33 and ST2 + regulatory T cells increases immune cell-mediated hepatitis and activated NK cell liver infiltration. Am J Physiol Gastrointest Liver Physiol 311:G313–G323CrossRefPubMed
33.
Zurück zum Zitat Oshio T et al (2017) Nuclear expression of IL-33 in epidermal keratinocytes promotes wound healing in mice. J Dermatol Sci 85:106–114CrossRefPubMed Oshio T et al (2017) Nuclear expression of IL-33 in epidermal keratinocytes promotes wound healing in mice. J Dermatol Sci 85:106–114CrossRefPubMed
34.
Zurück zum Zitat Oyoshi MK et al (2016) Thymic stromal lymphopoietin and IL-33 promote skin inflammation and vaccinia virus replication in a mouse model of atopic dermatitis. J Allergy Clin Immunol 138:283–286CrossRefPubMedPubMedCentral Oyoshi MK et al (2016) Thymic stromal lymphopoietin and IL-33 promote skin inflammation and vaccinia virus replication in a mouse model of atopic dermatitis. J Allergy Clin Immunol 138:283–286CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Peine M et al (2016) IL-33 in T cell differentiation, function, and immune homeostasis. Trends Immunol 37:321–333CrossRefPubMed Peine M et al (2016) IL-33 in T cell differentiation, function, and immune homeostasis. Trends Immunol 37:321–333CrossRefPubMed
36.
Zurück zum Zitat Popovic B et al. (2017) IL-33/ST2 pathway drives regulatory T cell dependent suppression of liver damage upon cytomegalovirus infection. PLoS Pathog. 13, e1006345 Popovic B et al. (2017) IL-33/ST2 pathway drives regulatory T cell dependent suppression of liver damage upon cytomegalovirus infection. PLoS Pathog. 13, e1006345
38.
Zurück zum Zitat Ryu WI et al (2016) IL-33 down-regulates filaggrin expression by inducing STAT3 and ERK phosphorylation in human keratinocytes. J Dermatol Sci 82:131–134CrossRefPubMed Ryu WI et al (2016) IL-33 down-regulates filaggrin expression by inducing STAT3 and ERK phosphorylation in human keratinocytes. J Dermatol Sci 82:131–134CrossRefPubMed
40.
Zurück zum Zitat Savinko T et al (2013) ST2 regulates allergic airway inflammation and T-cell polarization in epicutaneously sensitized mice. J Investig Dermatol 133:2522–2529CrossRefPubMed Savinko T et al (2013) ST2 regulates allergic airway inflammation and T-cell polarization in epicutaneously sensitized mice. J Investig Dermatol 133:2522–2529CrossRefPubMed
42.
Zurück zum Zitat Schmitz J et al (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:479–490CrossRefPubMed Schmitz J et al (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:479–490CrossRefPubMed
43.
Zurück zum Zitat Sehra S et al (2008) IL-4 is a critical determinant in the generation of allergic inflammation initiated by a constitutively active Stat6. J Immunol 180:3551–3559CrossRefPubMed Sehra S et al (2008) IL-4 is a critical determinant in the generation of allergic inflammation initiated by a constitutively active Stat6. J Immunol 180:3551–3559CrossRefPubMed
44.
45.
Zurück zum Zitat Sehra S et al (2016) Increased Th2 activity and diminished skin barrier function cooperate in allergic skin inflammation. Eur J Immunol 46:2609–2613CrossRefPubMedPubMedCentral Sehra S et al (2016) Increased Th2 activity and diminished skin barrier function cooperate in allergic skin inflammation. Eur J Immunol 46:2609–2613CrossRefPubMedPubMedCentral
46.
Zurück zum Zitat Seltmann J et al (2015) IL-33 impacts on the skin barrier by downregulating the expression of filaggrin. J Allergy Clin Immunol 135:1659–1661.e4CrossRefPubMed Seltmann J et al (2015) IL-33 impacts on the skin barrier by downregulating the expression of filaggrin. J Allergy Clin Immunol 135:1659–1661.e4CrossRefPubMed
47.
Zurück zum Zitat Serezani AP et al (2017) IL-4 impairs wound healing potential in the skin by repressing fibronectin expression. J Allergy Clin Immunol 139:142–151.e5CrossRefPubMed Serezani AP et al (2017) IL-4 impairs wound healing potential in the skin by repressing fibronectin expression. J Allergy Clin Immunol 139:142–151.e5CrossRefPubMed
48.
Zurück zum Zitat Soumelis V et al (2002) Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 3:673–680CrossRefPubMed Soumelis V et al (2002) Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 3:673–680CrossRefPubMed
49.
Zurück zum Zitat Souwer Y et al (2010) IL-17 and IL-22 in atopic allergic disease. Curr Opin Immunol 22:821–826CrossRefPubMed Souwer Y et al (2010) IL-17 and IL-22 in atopic allergic disease. Curr Opin Immunol 22:821–826CrossRefPubMed
50.
Zurück zum Zitat Turner MJ et al (2012) T helper cell subsets in the development of atopic dermatitis. J Drugs Dermatol 11:1174–1178PubMed Turner MJ et al (2012) T helper cell subsets in the development of atopic dermatitis. J Drugs Dermatol 11:1174–1178PubMed
51.
Zurück zum Zitat Turner MJ et al (2013) Topical application of a vitamin D analogue exacerbates atopic dermatitis and induces the atopic dermatitis-like phenotype in Stat6VT mice. Pediatr Dermatol 30:574–578CrossRefPubMedPubMedCentral Turner MJ et al (2013) Topical application of a vitamin D analogue exacerbates atopic dermatitis and induces the atopic dermatitis-like phenotype in Stat6VT mice. Pediatr Dermatol 30:574–578CrossRefPubMedPubMedCentral
52.
Zurück zum Zitat Turner MJ et al (2014) STAT6-mediated keratitis and blepharitis: a novel murine model of ocular atopic dermatitis. Investig Ophthalmol Vis Sci 55:3803–3808CrossRef Turner MJ et al (2014) STAT6-mediated keratitis and blepharitis: a novel murine model of ocular atopic dermatitis. Investig Ophthalmol Vis Sci 55:3803–3808CrossRef
53.
Zurück zum Zitat Turnquist HR et al (2011) IL-33 expands suppressive CD11b + Gr-1(int) and regulatory T cells, including ST2L + Foxp3 + cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol 187:4598–4610CrossRefPubMedPubMedCentral Turnquist HR et al (2011) IL-33 expands suppressive CD11b + Gr-1(int) and regulatory T cells, including ST2L + Foxp3 + cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol 187:4598–4610CrossRefPubMedPubMedCentral
54.
Zurück zum Zitat Vasanthakumar A et al (2015) The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue-resident regulatory T cells. Nat Immunol 16:276–285CrossRefPubMed Vasanthakumar A et al (2015) The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue-resident regulatory T cells. Nat Immunol 16:276–285CrossRefPubMed
55.
Zurück zum Zitat Yin H et al (2013) IL-33 accelerates cutaneous wound healing involved in upregulation of alternatively activated macrophages. Mol Immunol 56:347–353CrossRefPubMed Yin H et al (2013) IL-33 accelerates cutaneous wound healing involved in upregulation of alternatively activated macrophages. Mol Immunol 56:347–353CrossRefPubMed
56.
Zurück zum Zitat Yin H et al (2013) IL-33 promotes Staphylococcus aureus-infected wound healing in mice. Int Immunopharmacol 17:432–438CrossRefPubMed Yin H et al (2013) IL-33 promotes Staphylococcus aureus-infected wound healing in mice. Int Immunopharmacol 17:432–438CrossRefPubMed
57.
Zurück zum Zitat Yoo J et al (2005) Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J Exp Med 202:541–549CrossRefPubMedPubMedCentral Yoo J et al (2005) Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J Exp Med 202:541–549CrossRefPubMedPubMedCentral
Metadaten
Titel
Phenotyping acute and chronic atopic dermatitis-like lesions in Stat6VT mice identifies a role for IL-33 in disease pathogenesis
verfasst von
Sonia C. DaSilva-Arnold
Anita Thyagarajan
Leroy J. Seymour
Qiaofang Yi
Joshua R. Bradish
Mohammed Al-Hassani
Hongming Zhou
Nikolajs J. Perdue
Val Nemeth
Aleksandar Krbanjevic
Ana P. M. Serezani
Matthew R. Olson
Dan F. Spandau
Jeffrey B. Travers
Mark H. Kaplan
Matthew J. Turner
Publikationsdatum
24.01.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Dermatological Research / Ausgabe 3/2018
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-018-1807-y

Weitere Artikel der Ausgabe 3/2018

Archives of Dermatological Research 3/2018 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.